AAGH Stock Overview
Operates as a biotechnology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
America Great Health Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.024 |
| 52 Week Low | US$0.0001 |
| Beta | 6.02 |
| 11 Month Change | 0% |
| 3 Month Change | -75.00% |
| 1 Year Change | -93.75% |
| 33 Year Change | -99.69% |
| 5 Year Change | -90.20% |
| Change since IPO | -87.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAGH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | -93.8% | 16.1% | 31.6% |
Return vs Industry: AAGH underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: AAGH underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| AAGH volatility | |
|---|---|
| AAGH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine AAGH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Mike Wang | www.americagreathealth.us |
America Great Health operates as a biotechnology company in the United States. It focuses on the research and development of protein and peptide small molecular drugs; and the manufacturing and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and regenerative medicine and nutritional dietary supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017.
America Great Health Fundamentals Summary
| AAGH fundamental statistics | |
|---|---|
| Market cap | US$10.59m |
| Earnings (TTM) | -US$873.01k |
| Revenue (TTM) | US$273.71k |
38.7x
P/S Ratio-12.1x
P/E RatioIs AAGH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAGH income statement (TTM) | |
|---|---|
| Revenue | US$273.71k |
| Cost of Revenue | US$20.66k |
| Gross Profit | US$253.05k |
| Other Expenses | US$1.13m |
| Earnings | -US$873.01k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.000041 |
| Gross Margin | 92.45% |
| Net Profit Margin | -318.96% |
| Debt/Equity Ratio | -50.7% |
How did AAGH perform over the long term?
See historical performance and comparison